Vivos Therapeutics Inc. (VVOS): Price and Financial Metrics
VVOS Price/Volume Stats
Current price | $4.47 | 52-week high | $48.79 |
Prev. close | $4.50 | 52-week low | $2.73 |
Day low | $4.40 | Volume | 59,300 |
Day high | $4.77 | Avg. volume | 125,430 |
50-day MA | $5.87 | Dividend yield | N/A |
200-day MA | $7.96 | Market Cap | 5.95M |
VVOS Stock Price Chart Interactive Chart >
VVOS POWR Grades
- VVOS scores best on the Growth dimension, with a Growth rank ahead of 87.74% of US stocks.
- The strongest trend for VVOS is in Growth, which has been heading up over the past 64 days.
- VVOS's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
VVOS Stock Summary
- VVOS has a higher market value than just 6.88% of US stocks; more precisely, its current market capitalization is $14,067,782.
- VIVOS THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.93% of US listed stocks.
- The volatility of VIVOS THERAPEUTICS INC's share price is greater than that of 99.8% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to VIVOS THERAPEUTICS INC are MDXG, RDFN, CAPL, EZFL, and BIOL.
- Visit VVOS's SEC page to see the company's official filings. To visit the company's web site, go to www.vivoslife.com.
VVOS Valuation Summary
- In comparison to the median Healthcare stock, VVOS's price/sales ratio is 76.19% lower, now standing at 1.
- VVOS's price/earnings ratio has moved up 12.4 over the prior 37 months.
Below are key valuation metrics over time for VVOS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VVOS | 2023-12-29 | 1.0 | 323.9 | -1.0 | -1.0 |
VVOS | 2023-12-28 | 1.0 | 326.1 | -1.0 | -1.0 |
VVOS | 2023-12-27 | 1.0 | 310.9 | -0.9 | -1.0 |
VVOS | 2023-12-26 | 0.9 | 293.5 | -0.9 | -0.9 |
VVOS | 2023-12-22 | 0.9 | 295.7 | -0.9 | -1.0 |
VVOS | 2023-12-21 | 1.0 | 306.5 | -0.9 | -1.0 |
VVOS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VVOS has a Quality Grade of D, ranking ahead of 23.33% of graded US stocks.
- VVOS's asset turnover comes in at 0.795 -- ranking 38th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VVOS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2020-12-31 | 0.795 | 0.797 | 5.192 |
2020-12-31 | 0.795 | 0.797 | 5.192 |
VVOS Price Target
For more insight on analysts targets of VVOS, see our VVOS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $12.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Vivos Therapeutics Inc. (VVOS) Company Bio
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.
Latest VVOS News From Around the Web
Below are the latest news stories about VIVOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VVOS as an investment opportunity.
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSALITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including mild to severe obstr |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning! |
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?Redhill Biopharma stock is falling on Thursday as shares of RDHL give up some of the gains they made throughout the week. |
Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?Vivos Therapeutics stock is falling on Thursday but that's only after VVOS shares experienced a massive rally on Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
VVOS Price Returns
1-mo | -14.86% |
3-mo | -63.18% |
6-mo | -14.00% |
1-year | -45.98% |
3-year | -97.43% |
5-year | N/A |
YTD | -64.07% |
2023 | 23.78% |
2022 | -82.13% |
2021 | -61.93% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...